Biogen Inc.
A biopharmaceutical company focused on the brain and nervous system, Biogen makes treatments for multiple sclerosis, spinal muscular atrophy, ALS, and Alzheimer's — with brands like TYSABRI, SPINRAZA, and the Alzheimer's drug LEQEMBI it co-markets with Eisai. It was founded in 1978 in Geneva by academic scientists (including two future Nobel laureates) and later moved to Cambridge, Massachusetts, where it remains. Its name is a mash-up of "Biotechnology Geneva," and its roots stretch back to the dawn of the biotech industry.
Granted 9.0K
Granted 1.5K
Granted 7.2K
Granted 31.5K
Granted 8.7K · Bought 3
Granted 1.5K
Granted 6.9K
Granted 1.5K
Granted 1.5K
Granted 5.0K
Granted 2.0K
Granted 10.4K · Sold 3.9K
Granted 1.5K
Granted 6.0K
Granted 1.5K
Granted 1.5K
Granted 3.9K
Granted 4.0K
Granted 1.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Alexander Susan HEVP Chief Legal Officer · 6 transactions | +3.9% | 58.5K | 9.0K | — | — |
| Rowinsky Eric KDirector · 1 transaction | +6.2% | 25.8K | 1.5K | — | — |
| Gregory GingerEVP, Human Resources · 6 transactions | +27.1% | 22.4K | 7.2K | — | — |
| Viehbacher ChristopherPresident and CEO, Director · 6 transactions | +31.8% | 21.1K | 31.5K | — | — |
| Murphy NicoleHead of Pharm Ops and Tech · 7 transactions | +39.5% | 19.6K | 8.7K | 3 | — |
| Sherwin Stephen ADirector · 1 transaction | +11% | 15.2K | 1.5K | — | — |
| Izzar RachidHead of Global Product Strat. · 6 transactions | +86.2% | 11.8K | 6.9K | — | — |
| Mantas Jesus BDirector · 1 transaction | +15.4% | 11.3K | 1.5K | — | — |
| Hawkins William ADirector · 1 transaction | +17% | 10.4K | 1.5K | — | — |
| Kramer RobinChief Financial Officer · 6 transactions | +12.6% | 9.0K | 5.0K | — | — |
| Freire Maria CDirector · 1 transaction | +29.4% | 8.8K | 2.0K | — | — |
| Singhal PriyaHead of Development · 11 transactions | +48.2% | 8.0K | 10.4K | — | 3.9K |
| Langer SusanDirector · 1 transaction | +29.3% | 6.6K | 1.5K | — | — |
| Keeney AdamHead of Corporate Development · 6 transactions | +124.3% | 6.4K | 6.0K | — | — |
| Patolawala Monish DDirector · 1 transaction | +40.6% | 5.2K | 1.5K | — | — |
| Minor LloydDirector · 1 transaction | +63.5% | 3.9K | 1.5K | — | — |
| Pangalos Menelas NDirector · 2 transactions | — | 3.9K | 3.9K | — | — |
| Grogan JaneHead of Research · 6 transactions | +69.3% | 3.2K | 4.0K | — | — |
| Godbout SeanChief Accounting Officer · 10 transactions | +192.8% | 1.4K | 1.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -3.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.